Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026 -

DUBLIN--()--The "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" report has been added to's offering.

This report offers comprehensive clinical and non clinical insight on the recent trends and the opportunities that the market has been experiencing at a regional and at global level. The cancer antibody drug conjugate market has been witnessing tremendous growth and offers unexplored potential to pharmaceutical companies involved in development of anti cancer therapeutics market. This new drug class is widely accepted in the form of monotherapy as well as combinational therapy among the Breast Cancer, Acute Leukemia and Lymphoma patients. In addition to the various strategies that have been employed by the major key players of the market, the report also delivers information regarding the achievements, valuable highlights and all the progressive compilations that have been made in the market.

Report Highlights:

  • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs
  • Marketed Cancer Antibody Drug Conjugate: 9 Drugs
  • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026
  • Majority of Drug Trials Are For Second Line Therapy Or Greater
  • USA Dominates Cancer ADC Clinical Trials Landscape: > 180 Drugs
  • Tubulin Modulators Dominates Cancer ADC Trials: > 60 Drugs
  • Sales, Market Opportunity, Clinical Trials Graphs: > 100 Graphs

After the approval of first ADC i.e. Pfizer's Mylotarg in year 2000, the antibody drug conjugates are continuously witnessing exponential growth and are emerging as most prominent therapeutic approach for the management of cancer. After the withdrawal of Mylotarg, two new antibody drug conjugates entered into the market, which took the market to the next level. Further, the Mylotarg was also reintroduced into the market in 2017 and currently 9 cancer antibody drug conjugates are available in the market, which are continuously boosting the drug conjugates market.

The drugs launched under antibody drug conjugates class have been designed in a way such that they show promising targeting activity. The drugs incorporate antibody specificity as well as cell killing activity of cytotoxic agents that have been chemically conjugated. Other than the efficient targeting activity, the drugs under it have been prominent in showing various other clinical applications. With 9 antibody drug conjugates available in the market and all being tremendously successful, namely Lumoxiti, Polivy, Mylotarg, Besponsa, Kadcyla and Adcetris, this therapeutic method have been classified as a potent treatment in oncology.

An advantage that is associated with this class of therapeutics is that it has the ability to effectively identify the cells that are foreign or not healthy. In the present scenario, all the clinicians, non-clinicians and the patients are getting inclined towards it as it has overcome the challenge that were highlighted during other treatment procedure i.e. toxicity related issues. The current trend that the market states is that this novel therapeutic regimen has now become a part of mainstream oncology healthcare system and has achieved significant warmth in the oncology department all around the globe.

Key Topics Covered:

1. Introduction to Antibody Drug Conjugates (ADCs)

1.1 Overview

1.2 Historical Development of ADCs

2. Evolution of Antibody Drug Conjugates

2.1 Advancements in ADCs

2.2 Components of ADCs

3. Antibody Drug Conjugates - Mechanism of Action

3.1 Antigen-Antibody Interaction

3.2 Release of Payload

3.3 Mechanism of Cytotoxicity

4. Need of Antibody Drug Conjugates

5. Role of ADCs in Cancer Management

5.1 Breast Cancer

5.2 Leukemia

5.3 Lymphoma

5.4 Other Cancers

6. Antibody Drug Conjugate Market Analysis

6.1 Overview

6.2 Current Market Scenario

6.3 ADCs Market Segmentation

6.3.1 Regional Segmentation

6.3.2 Segmentation By Products

7. Global - Cancer Antibody Drug Conjugate Market Insights

7.1 US

7.2 Europe

7.3 Japan

7.4 China

7.5 India

7.6 South Korea

8. Antibody Drug Conjugates - Availability, Dosage & Price Analysis

8.1 Mylotarg (Gemtuzumab ozogamicin)

8.2 Adcetris (Brentuximab vedotin)

8.3 Kadcyla (Trastuzumab emtansine)

8.4 Besponsa (Inotuzumab ozogamicin)

8.5 Lumoxiti (Moxetumomab pasudotox)

8.6 Polivy (Polatuzumab vedotin)

8.7 Enhertu (Fam-Trastuzumab Deruxtecan-Nxki)

8.8 Padcev (Enfortumab Vedotin)

9. Antibody Drug Conjugates - Sales Insight

9.1 Kadcyla

9.2 Adcetris

9.3 Polivy

10. Antibody Drug Conjugates - Clinical Pipeline Insight 2020 - 2026

10.1 By Phase

10.2 By Indication

10.3 By Company

10.4 By Patient Segment

10.5 By Country

10.6 By Mechanism of Action

11. Global Cancer Drug Conjugates Clinical Pipeline By Company, Indication & Phase

11.1 Research

11.2 Preclinical

11.3 Clinical

11.4 Phase-0

11.5 Phase-I

11.6 Phase-I/II

11.7 Phase-II

11.8 Phase-II/III

11.9 Phase-III

11.10 Preregistration

11.11 Registered

12. Marketed Cancer Drug Conjugates Clinical Insight

12.1 Adcetris

12.2 Mylotarg

12.3 Junovan/Mepact

12.4 Kadcyla

12.5 Besponsa

12.6 Zevalin/ Zevamab


12.8 OncoScint CR/OV

12.9 Enhertu

13. Global Cancer an Antibody Drug Conjugates Market Dynamics

13.1 Favorable Parameters

13.2 Challenges for Antibody Drug Conjugates Market

14. Antibody Drug Conjugates Market - Future Outlook

15. Competitive Landscape

15.1 AstraZeneca plc

15.2 Genentech

15.3 Roche

15.4 Takeda Pharmaceuticals

15.5 Pfizer

15.6 Oxford BioTherapeutics

15.7 Heidelberg Pharma

15.8 Synthon

15.9 Mersana Therapeutics

15.10 Progenics Pharmaceuticals

15.11 Astellas Pharma

15.12 Bristol Mayer Squibb

15.13 Seattle Genetics

15.14 Immunogen

15.15 Celldex Therapeutics

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900